Brief: Virios Therapeutics Announces Initial FDA Feedback For Lead Drug Candidate Trial

Dogwood Therapeutics

24/04/2023 23:03

April 24 (Reuters) - Virios Therapeutics Inc  VIRI.O :
    * VIRIOS THERAPEUTICS ANNOUNCES INITIAL FDA FEEDBACK ON
PROPOSED
IMC-1 PHASE 3 PROGRAM FOR TREATMENT OF FIBROMYALGIA
    * VIRIOS THERAPEUTICS ANNOUNCES INITIAL FDA FEEDBACK ON
PROPOSED
IMC-1 PHASE 3 PROGRAM FOR TREATMENT OF FIBROMYALGIA
    * VIRIOS THERAPEUTICS INC - FINAL TOXICOLOGY RESULTS TO BE
SUBMITTED TO FDA IN MAY 2023-
    * VIRIOS - IMC-1 PHASE 3 PROPOSED PROGRAM CONSIDERED
ACCEPTABLE
BASED ON INITIAL FDA FEEDBACK PENDING REVIEW OF FINAL CHRONIC
TOXICOLOGY PROGRAM RESULTS

Source text for Eikon:  ID:nGNX8VPhxk 
Further company coverage:  VIRI.O 

 ((Reuters.Briefs@thomsonreuters.com;))